Please login to the form below
Novartis reveals USD 400m of further cuts
Novartis reveals plans to make additional savings of USD 400m at its pharmaceutical business in addition to the previously announced USD 1bn of cuts
Swiss-based pharmaceutical company Novartis has revealed plans to make additional savings of USD 400m at its pharmaceutical business in addition to the previously announced USD 1bn of cuts, according to local media reports.
The SonntagsZeitung newspaper said that Novartis' head of pharmaceuticals, Thomas Ebeling, had confirmed the new plans in discussions with analysts at the group's Pharma Brand and Business Review on 12 September.
Novartis instituted the cuts to make savings in marketing and sales, where costs rose 11 per cent in 2006.
The newspaper also reported that Novartis was going to make big cuts in its US salesforce after recent product setbacks, after the company expanded it by between 6,000-7,000 in 2006.
Share
Related Hub content
Featured jobs
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Senior Medical Writer
-
Salary TBC
-
Senior Medical Writer
-
Up to £50, 000 with Benefits
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Project Manager/ Account Manager
-
Salary TBC
-
Digital Account Director
-
Salary TBC
-
Senior Medical Writer
-
Great salary and benefits
-
Account Director, Medical Education
-
Salary TBC
Subscribe to our email news alerts
- Drug launches to watch in 2019
- Novartis first to benefit from NICE advice on ‘patient preference’
- GW Pharma's cannabis-based medicine to be tested in dementia
- Immuno-oncology in 2019: the rapid evolution continues
- Novartis’ Egatan gains US approval for neglected tropical disease
- Keytruda combo outshines Opdivo in kidney cancer
- As government rushes through no-deal legislation, UK biotech repeats Brexit plea
- Cell and gene therapy
- Forster Communications and Cello Health launch sustainability service
- Excellent teamwork and interdepartmental collaboration lead to double promotion at Porterhouse Medical
- New ‘NHSX’ unit will lead health service digital transformation
- Gyroscope's gene therapy given to first dry AMD patient
PMHub
Publicis Resolute
Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...
Latest intelligence
- Cell and gene therapy
- Tackling the manufacturing cost and complexity challenges...
- 2019: CRISPR and therapeutic gene editing comes of age
- Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
- The 10-year Web Challenge
- Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Quick links
Infographics
